n-9 PUFA, endogenously synthesized from oleic acid (18:1n-9) in an EFA-deficient state. Although Elovl5, a fatty acid elongase, has long been known to selectively elongate C18 and C20 PUFAs, it can use 18:1n-9 as a substrate for the synthesis of Mead acid under C20 PUFAdeficient, but not -sufficient, conditions. We found, by an in vitro enzyme assay, that the microsomal fraction obtained from PUFAdeficient, but not -sufficient, cells showed significant Elovl5 activity toward 18:1n-9, with no effect on its constitutive activity toward 18:3n-6, implying that Elovl5 acquires the activity toward 18:1n-9 under the PUFAdeficient conditions at the enzyme level. Further biochemical analysis revealed that Elovl5 was phosphorylated in the C20 PUFA-supplemented cells, and that treatment with an inhibitor of glycogen synthase kinase 3 (GSK3) completely abolished the phosphorylation of Elovl5 and retained the Elovl5 activity toward 18:1n-9, even in the presence of C20 PUFA. Finally, mutation of putative phosphorylation sites (T281A/S283A/S285A) on Elovl5 did not decrease the activity of Elovl5 toward 18:1n-9 by supplementation with C20 PUFA, suggesting that the phosphorylation of Elovl5 contributed to a change in substrate preference. Thus, by changing its substrate specificity in an EFAdeficient state, Elovl5 is able to regulate the synthesis of Mead acid to maintain levels of longchain PUFAs.
Polyunsaturated fatty acids (PUFAs) are important components of biological membranes and the precursors of bioactive substances such as prostaglandins, which mediate numerous physiological and pathological processes (1) .
Mammals are unable to synthesize n-6 or n-3 series PUFAs and must obtain them from diets.
Therefore, PUFAs such as linoleic acid (18:2n-6) and a-linolenic acid (18:3n-3) are called essential fatty acids (EFAs), which can be converted to long-chain and highly unsaturated fatty acids, such as arachidonic acid (20:4n-6) and eicosapentaenoic acid (EPA, 20:5n-3), through elongation and desaturation reactions (Fig. 1A) .
EFA-deficiency causes impaired growth, skin lesions, and infertility in rodents (2, 3) , and occurs in humans when the contents of EFAs in diets are less than 1-2% of the total calories (5) .
Indeed, EFA-deficiency is observed in patients with intestinal lipid malabsorption and in patients that receive total parenteral nutrition with fat restriction (6, 7) .
In the EFA-deficient state, 5,8,11eicosatrienoic acid (Mead acid, 20:3n-9) is endogenously synthesized from 18:1n-9 (oleic acid) ( Fig. 1A) (4) , and plasma and tissue levels of Mead acid are used as a diagnostic indicator of EFA-deficiency (2, 3) . Among infants in intensive care units, those with a high level of Mead acid grew more slowly than other infants despite receiving similar amounts of macronutrients such as proteins and carbohydrates (8) . Mead acid is sometimes detected in human cancers such as breast cancer (9) and prostate cancer (10) , suggesting that some cancer tissues are in the EFA-deficient state.
Mead acid is thought to be used as a substitute for essential PUFAs in biological membranes. For example, incorporation of PUFAs such as arachidonic acid (20:4n-6) into phospholipids is required for the efficient transport of dietary lipids in the intestine and the liver (11, 12) , and
Mead acid in membrane phospholipids can rescue the impaired hepatic lipid transport in the EFA-deficient state (13). Oxidative metabolites of Mead acid participate in both proinflammatory (14) and anti-inflammatory signaling pathways (15) , suggesting that Mead acid at least partly compensates for the reduced levels of n-6 and n-3 PUFAs. Mead acid also exerts anti-angiogenic activity to attenuate the activity of osteoblasts (16, 17) and to inhibit tumorigenesis in certain types of cancer (18) . Moreover, intraperitoneal injection of Mead acid ameliorates allergic skin inflammation in the murine contact hypersensitivity model (19) . Elucidation of Mead acid synthesis and metabolism may therefore contribute to the fields of immunology and cancer as well as to development of a novel strategy to treat patients with EFA-deficiency.
We previously showed that Mead acid is produced from oleic acid (18:1n-9) by two desaturation enzymes (Fads1 and Fads2) and one elongation enzyme (Elovl5) (20) (Fig. 1A) .
These three enzymes also participate in the synthesis of 20:4n-6 from 18:2n-6 and the synthesis of 20:5n-3 from 18:3n-3 ( Fig. 1A) .
Elovl, a transmembrane protein residing in the endoplasmic reticulum (ER), is one of group of enzymes that control the rate of elongation of fatty acids with a chain length of more than 16 carbon atoms. The Elovl family is composed of seven distinct subtypes (Elovl1-7) in mammals, and each Elovl enzyme has a defined substrate specificity depending on the chain length or degree of unsaturation of fatty acids (21) . However, there is a discrepancy regarding the substrate specificity of Elovl5. While Elovl5 generally elongates C18 and C20 PUFAs in mammals (22, 23) , we have demonstrated that Elovl5 had activity toward the C18 monounsaturated fatty acid 18:1n-9 in an elongation assay using the microsomal fraction obtained from cells in an EFA-deficient state, and that this elongation activity was involved in the production of Mead acid in the cells (20) .
Moreover, there was a dramatic increase of 20:1n-9 in tissues of animals fed an EFAdeficient diet (20) , supporting the conversion of 18:1n-9 to 20:1n-9 in vivo ( Fig. 1A Thus, we found a novel regulatory mechanism in which Elovl5 changes the substrate preference by a post-translational modification.
Results

The elongation products of Elovl5 in n-9 and n-6 fatty acid pathways are differentially controlled by PUFAs
We previously showed that NIH3T3 cells cultured in a medium containing 10% (v/v) fetal bovine serum (FBS) produced significant amounts of Mead acid, a marker fatty acid of EFA-deficiency (20) . In fact, the PUFA level in 10% FBS is much lower than that in mouse plasma ( Fig. S1 ), upon addition of PUFAs [25 µM arachidonic acid (20:4n-6) + 25 µM EPA (20:5n-3)] to the culture medium, the level of Mead acid was greatly decreased ( Fig. 2A and B) . Treatment with PUFAs also reduced the intermediate products (18:2n-9, 20:1n-9, and 20:2n-9) for the synthesis of Mead acid in the n-9 fatty acid (FA) pathway ( Fig. 2A and B ). PUFAs.
Adding PUFAs decreased the cellular levels of both 18:1n-9 and 20:1n-9 ( Fig. 2A and B ). The level of 20:1n-9 was not increased by adding 18:1n-9 to the PUFA-treated cells ( Fig. S3A and   B ). Thus, the decrease of 20:1n-9 was not due to the reduction of 18:1n-9, a direct precursor for 20:1n-9. It is more likely that it was caused by the reduced elongation activity of Elovl5 from 18:1n-9 to 20:1n-9. On the other hand, the level of 20:3n-6 was not affected by the addition of PUFAs ( Fig. 2C ). 20:3n-6 is produced through the elongation of 18:2n-6 and 18:3n-6 by Elovl5 ( Fig. 1A ). Although 18:3n-6 and 20:2n-6 were nearly undetectable in NIH3T3 cells under the experimental conditions used, the above result suggests that the elongation activity of Elovl5 in the n-6 FA pathway was not altered by PUFAs (see Fig. 1A ). Taken together, these results raised the possibility that the Elovl5 activities toward n-9 and n-6 FAs are differentially controlled by PUFAs.
The addition of PUFAs to NIH3T3 cells decreased the mRNA level of Elovl5 by about 30% (Fig. 2D ), which is consistent with the previous observation that PUFAs suppress the hepatic expression of Elovl5 mRNA via inactivation of the LXRa-SREBP1c pathway (24) . However, western blots revealed that PUFAs did not significantly change the protein expression of Elovl5 ( Fig. 2E ). Thus, it is unlikely that the decreased level of 20:1n-9 in the presence of PUFAs is due to the reduction of the Elovl5 protein level.
Effect of PUFAs on Elovl5 activity toward 18:1n-9-CoA and 18:3n-6-CoA
We then evaluated the elongation activity of 
Cellular amount of C20 PUFAs is related to the Elovl5 activity toward 18:1n-9-CoA
We tested whether the addition of C18 PUFAs, linoleic acid (18:2n-6) and a-linolenic acid (18:3n-3), also reduced the Elovl5 activity toward 18:1n-9. The Elovl5 activity in NIH3T3 cells treated with a mixture of 25 µM 18:2n-6 and 25 µM 18:3n-3 was decreased by only 70%, relative to more than 90% reduction in the cells treated with C20 PUFAs (Fig. 4A ). Since C18
PUFAs could be converted to C20 PUFAs in the cell, we examined whether the reduced Elovl5 activity was due to the C18 PUFAs themselves or their elongation products, C20 PUFAs. In fact, treating the cells with C18 PUFAs increased the cellular content of C20 PUFAs (20:3n-9, 20:3n-6, 20:4n-6 and 20:5n-3) as well as C18 PUFAs (18:2n-6 and 18:3n-3) ( Fig. 4B) , whereas the addition of C20 PUFAs increased only the cellular content of C20 PUFAs and slightly decreased the content of C18 PUFAs. We then attempted to suppress the conversion of C18 PUFAs to C20 PUFAs in the cells treated with C18 PUFAs by adding TOFA (5-(tetradecyloxy)-
2-furancarboxylic acid), an inhibitor of acetyl
CoA carboxylase that is an essential enzyme for the production of malonyl-CoA (Fig. 4C ). The increase of C20 PUFAs in the cells treated with C18 PUFAs was appreciably suppressed by TOFA treatment (Fig. 4D ). Under the experimental conditions used, the suppression of the Elovl5 activity toward 18:1n-9 in the membrane fraction by C18 PUFAs was mostly cancelled by TOFA ( Fig. 4E) . Thus, the suppression of the Elovl5 activity toward 18:1n-9 by C18 PUFAs appeared to be due to C20
PUFAs produced from C18 PUFAs.
Elovl5 is phosphorylated in the presence of C20
PUFAs in a GSK3-dependent manner
The finding that C20 PUFAs greatly decreased are phosphorylated on residues corresponding to the phosphorylated sites in yeast Elo2 (28, 29) . We therefore examined whether the phosphorylation status of Elovl5 depends on the presence of C20 PUFAs in NIH3T3 cells. Phosphorylated proteins were separated using Phos-tag PAGE, and detected with an anti-Elovl5 antibody. Intriguingly, treatment of the cells with C20 PUFAs produced an up-shifted band of the Elovl5 protein ( Fig. 5A) , implying that the C20 PUFAs induced the phosphorylation of Elovl5.
The phosphorylation of Elo2 requires glycogen synthase kinase 3 (GSK3) (26) and occurs at sites that resemble GSK3 consensus sites (28) . The mobility shift of Elovl5 by C20 
Phosphorylation of Elovl5 in the C-terminal region regulates the elongation activity toward 18:1n-9
To further support the involvement of the Elovl5 phosphorylation in the loss of elongation activity toward 18:1n-9, we mutated some of the predicted phosphorylation sites of Elovl5. Nterminal 3xFLAG-tagged wild-type Elovl5 (WT-Elovl5) and T281A/S283A/S285A triple mutant Elovl5 (3A-Elovl5) were separately transfected into HEK293T cells (Fig. 5E ). The in vitro Elovl5 activity toward 18:1n-9 was increased in the cells transfected with WT-Elovl5 and 3A-Elovl5 (Fig.  5F ). The increases in activities were correlated with the increases in protein expression levels.
As expected, the Elovl5 activity in WT-Elovl5transfected cells was almost completely suppressed upon addition of C20 PUFA, whereas the Elovl5 activity in 3A-Elovl5-transfected cells remained unaffected by C20 PUFA (Fig. 5F) . The cellular level of 20:1n-9, a product of Elovl5, was also increased in the WT-Elovl5-and 3A-Elovl5transfected cells, while in the presence of C20 PUFAs, it was greatly decreased in the WT-Elovl5-transfected cells but not in the 3A-Elovl5transfected cells (Fig.  5G) . Thus, phosphorylation of T281/S283/S285 appears to be necessary for the complete loss of Elovl5 activity toward 18:1n-9 in C20 PUFA-treated cells. The lower expression levels of 3A-Elovl5 protein than WT-Elovl5 (Fig. 5E ) may support the idea that phosphorylation of Elovl5 protein confers its stability.
Discussion
Concerning the synthesis of Mead acid in an EFA-deficient state, it has generally been assumed that Elovl5 has much higher activity towards 18:2 and 18:3 than 18:1n-9 (23), which results in efficient synthesis of arachidonic acid and EPA and that Elovl5 uses 18:1n-9 in the EFAdeficiency state simply because the preferred substrates (18:2 and 18:3) were absent.
According to our study, this idea is partially true but insufficient. We showed that Elovl5 is constitutively phosphorylated and prefers 18:2 and 18:3 under normal nutritional conditions, but acquires an activity toward 18:1n-9 comparable to its activity toward 18:3n-6 by dephosphorylation of Elovl5 under the EFAdeficient conditions (Fig. 5H ). This molecular mechanism should result in more precise regulation to Elovl5 for the synthesis of Mead acid as a substitute for arachidonic acid or EPA in an EFA-deficient state. (31) . In a study concerning the molecular basis for the differences between Elovl5 that can elongate C20 PUFA to C22 PUFA and Elovl2 that can elongate C20 PUFA to C22 PUFA and then to C24 PUFA (32), replacement of some amino acids in the 6th and 7th transmembrane domains of Elovl2 with the equivalent residues from Elvol5 resulted in a loss of the unique Elovl2 conversion of C22 PUFA to C24 PUFA, while retaining the ability to convert C20 PUFA to C22 PUFA. All these studies pointed out that the intrinsic structure of Elovls, especially that of the transmembrane domains, are critical for determining the substrate or the product specificity. The present study postulates a unique mechanism underlying the determination of the substrate specificity of mammalian Elovls: phosphorylation at the cytosolic C-terminus (not in the transmembrane helices) of Elovl5 abolishes the activity toward 18:1n-9 without affecting the activity toward 18:3n-6. Among fatty acid elongases, posttranslational modification has been reported only in yeast Elo2.
Phosphorylation of Elo2 is increased in nutrientdepleted cells (26) or by inhibiting sphingolipid synthesis with myriocin, an inhibitor of serine palmitoyltransferase (27 
Elovl3
(fw, 5'-AGTGGGCCTCAAGCAAACCGTG-3'; rv, 5'-TGAGTGGACGCTTACGCAGGATGA-3'),
Elovl7
(fw, 5'-AGCTCATGGAGAACCGGAAG-3'; rv 5'-GTACCCCAGCCAGACATCAC-3'). The relative target gene expression was normalized on the basis of GAPDH content.
Fatty acid analysis by GC-MS
Cells were seeded in 6-well culture dishes at a density of 1.0 × 10 5 cells per well and cultured for 72 h. Total cellular lipids were extracted using the method of Bligh and Dyer (37) . Isolated lipids were methylated with 2.5% H2SO4 in methanol. The resulting fatty acid methyl esters were then extracted with hexane and quantified by gas chromatography-mass spectrometry (GC-MS) using a GC-MS QP2010 (Shimadzu) as described previously (13). 
